Catalyst Dossier · compiled by CeliA 🧫
Sensei Biotherapeutics, Inc. (SNSE)
Pharmaceutical Preparations · market cap $17M · as of 2026-07-19
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Sensei Biotherapeutics (SNSE) is a clinical-stage immunoncology company with a market cap of ~$19M and a single disclosed asset: SNS-101, an anti-VISTA antibody in Phase 2 for solid tumors. The company carries ~$152M in net cash against a ~$19M market cap, implying the market is assigning deeply negative value to the clinical program itself. A Phase 2 readout is estimated around June 2027.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| SNS-101 (anti-VISTA) | Phase 2 | Solid Tumor, Adult |
Price & technical context
3-month
-55.9%
6-month
+23.1%
12-month
+80.1%
52-wk range
$6.00–$35.07
vs 50-day MA
-47.6%
vs 200-day MA
-19.6%
Realized vol
157.1%
Max drawdown
-81.8%
Daily closes through 2026-06-08. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for SNSE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.